Phase l and Phase ll Study of S-1 + oxaliplatin (SOX) + cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type
Latest Information Update: 20 Feb 2019
At a glance
- Drugs Cetuximab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms JACCRO CC-06
- 19 Jan 2019 Results assessing for carcinoembryonic antigen at baseline and 4 weeks, and with observed survival time from 2 phase II trials (UMIN000004197 and UMIN000007022) presented at the 2019 Gastrointestinal Cancers Symposium.
- 24 Oct 2017 Results (n=92) of subanalysis of JACCRO CC-05 and JACCRO CC-06 assessing efficacy published in the Targeted Oncology.
- 21 Jan 2017 Results (n=92) of a sub analysis of JACCRO CC-05 and JACCRO CC-06 trials presented at the 2017 Gastrointestinal Cancers Symposium